Arcutis Reports Officer/Director Changes & Compensation
Ticker: ARQT · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, compensation, 8-K
Related Tickers: ARQT
TL;DR
Arcutis Biotherapeutics filed an 8-K about executive changes and compensation, but the details aren't in this snippet.
AI Summary
Arcutis Biotherapeutics, Inc. filed an 8-K on February 15, 2024, reporting events from February 12, 2024, concerning the departure or election of directors or officers and their compensatory arrangements. The specific individuals, roles, and financial details of these changes are not provided in the excerpt.
Why It Matters
Changes in executive leadership and compensation structures can signal strategic shifts or financial adjustments, potentially impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in key personnel and their compensation can introduce uncertainty regarding future company strategy and performance.
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — registrant
- February 12, 2024 (date) — date of earliest event reported
- February 15, 2024 (date) — filing date
FAQ
Which directors or officers departed or were elected?
The provided text does not specify the names of any departing or newly elected directors or officers.
What are the details of the compensatory arrangements mentioned?
The filing indicates compensatory arrangements were made, but the specific terms or dollar amounts are not detailed in this excerpt.
What was the earliest event reported in this 8-K?
The earliest event reported was on February 12, 2024.
When was this 8-K filed with the SEC?
This 8-K was filed on February 15, 2024.
What is the primary item information category for this 8-K?
The primary item information category is 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
Filing Stats: 775 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-02-15 16:20:39
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Select
Filing Documents
- arqt-20240212.htm (8-K) — 30KB
- 0001628280-24-005061.txt ( ) — 156KB
- arqt-20240212.xsd (EX-101.SCH) — 2KB
- arqt-20240212_lab.xml (EX-101.LAB) — 24KB
- arqt-20240212_pre.xml (EX-101.PRE) — 13KB
- arqt-20240212_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: February 15, 2024 By: /s/ Todd Franklin Watanabe Todd Franklin Watanabe President and Chief Executive Officer